Failure to Obtain Proper Consent for Antipsychotic Medications
Summary
The facility failed to ensure residents were informed of the risks, benefits, and alternatives before antipsychotic medications were administered, and it failed to obtain proper consent for those medications for three residents reviewed. The report states that the facility did not obtain prior consent before giving Zyprexa to one resident, did not obtain prior consent before giving Haldol to another resident, and accepted a consent signed by a resident with severely impaired cognitive skills for Zyprexa. One resident had diagnoses including dementia with agitation, hemiplegia and hemiparesis following cerebral infarction, hypertension, heart failure, generalized anxiety disorder, and emotional lability. The resident’s MDS showed a BIMS score of 03, indicating severe cognitive impairment, and no behavioral symptoms or psychosis indicators were noted. The record showed a physician order for Zyprexa 5 mg at bedtime for psychosis, and the MAR documented administration nightly over multiple days. The record review did not reveal a consent signed by the RP for Zyprexa. Another resident had diagnoses including hypertension, hemiplegia and hemiparesis following cerebral infarction, chronic respiratory failure, heart disease, seizures, alcoholic cirrhosis of the liver, and depression. The resident’s MDS showed a BIMS score of 06, indicating severe cognitive impairment, with no psychosis indicators or behavioral symptoms noted. The record showed orders for Haldol 5 mg for altered mental status, and the MAR documented doses given on multiple days. The record review did not reveal a consent signed by the RP for Haldol. A third resident had diagnoses including paranoid schizophrenia, cerebral infarction, anoxic brain damage, aphasia following cerebral infarction, and cognitive communication deficit. The resident’s MDS showed the resident was rarely or never able to be understood or to understand, and was severely impaired for cognitive skills for daily decision making. The resident signed the antipsychotic consent form, and the record showed Zyprexa 5 mg via PEG tube twice daily was ordered for paranoid schizophrenia and continued for months. During interview, the DON stated the resident would not be able to give consent based on the MDS, but also stated the resident was allowed to sign because he appeared able to follow commands visually. The DON and other staff stated consent was required before antipsychotic administration, and the facility policy stated informed consent was to be completed prior to initiation of new psychoactive medication.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.